Livelyhood’s most important evidence question is not how much weight its customers might lose. The platform centers its offer on drinking less, advertising semaglutide for people who do not want weight loss and tirzepatide for those who do. That positioning requires careful separation of three things: what the company promises to provide, what product a patient would actually receive, and what research establishes about that specific treatment. A familiar drug name does not, by itself, connect those three pieces.
This review examines Livelyhood’s homepage, terms, privacy policy, and refund policy, consulted October 19, 2026. Those documents describe an alcohol-focused telehealth service with independent clinicians, partner pharmacies, subscriptions, and several advertised prices. They offer useful operational detail, but leave important questions about formulations, billing, follow-up, and treatment outcomes unresolved. The clinical research considered here supplies context, not independent validation of Livelyhood. The practical goal is to distinguish documented service commitments from promotional claims before a prospective patient pays.
At a glance
- Primary purpose
- Livelyhood describes its platform as connecting patients with clinicians and pharmacies for evaluation and treatment of alcohol use disorder, rather than primarily as a weight-loss service.Sources: [4]
- Advertised medicines
- The homepage markets semaglutide and tirzepatide as “microdose” options and explicitly identifies use for alcohol use disorder as off-label.Sources: [7]
- Clinical responsibility
- Livelyhood Health, Inc. operates the platform; its terms assign clinical services to independently licensed professionals affiliated with OpenLoop Health.Sources: [6]
- Published prices
- Monthly plans start at an advertised $199 per month and three-month plans at $166 per month, but other first-month figures and discounts are not clearly reconciled.Sources: [7]
- Cancellation boundary
- Cancellation takes effect at the end of the current billing cycle. Medication cannot be returned or refunded after shipment under the stated policy.Sources: [5]
An alcohol-focused offer, not a conventional weight-loss program
Livelyhood’s privacy policy describes its purpose as evaluation and treatment of alcohol use disorder. Its homepage makes a more consumer-oriented distinction: semaglutide, labeled “microdose,” is marketed for people who want to drink less without losing weight; tirzepatide, also labeled “microdose,” is marketed for drinking less while losing some weight. These are the provider’s positioning statements, not demonstrated outcomes for either program. They should not be read as guarantees about drinking behavior or weight.
The homepage explicitly calls use for alcohol use disorder off-label. That disclosure matters, but it does not answer what evidence supports the particular regimen offered. The consulted documentation does not establish the exact route, presentation, or formulation of either advertised option. Nor does it present independently verified outcomes for Livelyhood patients. The term “microdose” therefore does not supply enough information to match this service to a particular clinical study or predict its effects.
Livelyhood also says its program can accompany 12-step programs, therapy, and other recovery approaches. It recommends at least six months for what it calls the best results, while offering plans as short as 30 days. That recommendation is a provider statement, not proof of an optimal duration or, by itself, a six-month contractual obligation. Our guide to what public provider documents can prove explains why a documented offer and demonstrated clinical effectiveness remain separate findings.
What the clinical evidence can—and cannot—add
The clinical context reviewed here includes STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide. These were randomized weight-management trials in adults with obesity or overweight plus a weight-related condition or complication, without diabetes. They were not evaluations of Livelyhood’s alcohol-treatment service. STEP 1 studied subcutaneous semaglutide over 68 weeks; SURMOUNT-1 studied subcutaneous tirzepatide over 72 weeks. Neither establishes outcomes for an unspecified “microdose” regimen supplied through this platform.
Both trials also reported tolerability limitations, including gastrointestinal adverse effects. Novo Nordisk funded STEP 1, and Eli Lilly funded SURMOUNT-1. Their findings cannot establish how much a Livelyhood patient would drink, whether that person would lose weight, or how a compounded preparation would perform. This is why a clinical trial is not a telehealth company performance report. The available clinical context does not establish efficacy for Livelyhood’s alcohol-focused offering; that is not the same as proving it ineffective.
Livelyhood’s terms separately acknowledge that compounded medications prescribed through the platform are not FDA approved. FDA says these preparations do not undergo its premarket review for safety, effectiveness, and quality, and recommends them when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not demonstrate clinical inequivalence. Readers should distinguish approved medicines from compounded preparations and ask which exact product is proposed, rather than treating an ingredient name as a complete evidence description.
Who evaluates patients and who can use the service
The terms identify Livelyhood Health, Inc. as the platform operator and describe Livelyhood as a healthcare technology company—not a medical practice, pharmacy, or insurer. Clinical services belong to independently licensed healthcare professionals affiliated with OpenLoop Health. That distinction helps identify responsibility: the platform arranges access, while a clinician makes treatment decisions. These are the company’s descriptions; this review did not independently verify individual professional licenses or the relationships among the listed organizations.
The advertised process begins with a short assessment, followed by review of medical history and treatment options. The terms allow evaluation through secure messaging or video when clinically appropriate. A clinician may decline to prescribe, recommend a different treatment, request more information, or require in-person care. Paying for a consultation does not guarantee a prescription. The documentation does not specify a standard review turnaround, so completing an assessment should not be mistaken for immediate clinical acceptance.
General access is limited to adults 18 or older who are in the United States during service. Although the terms advertise all 50 states and Washington, D.C., they expressly limit availability by service, professional and pharmacy licensing, and state law. Livelyhood says unavailable service will be identified during signup without a charge. The homepage also flags high-acuity needs, active crisis or acute suicidality, eating-disorder history, and BMI below an unspecified prescribing threshold as reasons someone likely would not fit the program.
The pharmacy chain is named; the product remains less specific
Livelyhood’s terms list four pharmacy partners: RedRock Pharmacy in Utah, Health Warehouse in Kentucky, Precision Medicine in New York, and Triad Rx in Alabama. They describe RedRock, Precision Medicine, and Triad Rx as 503A compounding pharmacies and Health Warehouse as a mail-order pharmacy. Their licensing descriptions are provider claims, not independent verification. The assigned pharmacy depends on the prescribed medicine, the patient’s state, and clinical considerations; the list does not mean every patient can choose any listed pharmacy.
This provides more visibility than an unnamed fulfillment network, but it does not identify what a particular patient would receive. The reviewed documents do not specify the exact route or presentation of the advertised semaglutide and tirzepatide. The refund policy also mentions FDA-approved oral medications without naming them or explaining their role in the program. Listing a pharmacy that compounds does not establish that every medicine it dispenses is compounded, or identify which partner would prepare a specific order.
The homepage promises discreet home delivery and describes arrival as quick, without a defined preparation, dispatch, or arrival deadline. For missing or damaged shipments, the policy requires contact within seven days of the expected delivery date and says Livelyhood will work with the pharmacy on a no-cost replacement. Separately, FDA advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. That guidance is relevant if an injectable product is prescribed; the public offer does not establish the route.
Published prices need a written, product-specific explanation
Livelyhood publishes actual prices, but their relationship is unclear. Its monthly block says “From $7/day or $199/month,” alongside $199 and $299 per month, lower figures of $149 and $249, and $50 off the first month. The three-month block similarly presents starting rates, paired amounts, and a first-month discount. The documentation does not clearly assign each figure to semaglutide or tirzepatide, so choosing a drug-price pairing would require an unsupported inference.
A separate promotion advertises $99 off a three-month plan, expressed as $33 per month off, while another homepage passage starts the first month at $169. These figures should remain visible rather than being collapsed into one supposedly definitive starting price. The daily amounts are advertising equivalents, not documented daily billing options. Likewise, a three-month plan labeled with a monthly amount does not establish whether the company collects monthly or requires an upfront payment.
The terms say Stripe processes payments, Livelyhood does not bill insurance, and card statements may display “OPNLP Health.” What remains unclear includes the consultation fee, plan inclusions, possible shipping, supplies or testing charges, renewal mechanics, and compatibility of promotions. Before purchase, the useful evidence is an itemized checkout showing the specific medicine and presentation, first charge, later charges, billing interval, and included services. Nothing reviewed establishes a price lock or a particular quantity of medication from the package duration alone.
| Offer | Published figures | Unresolved condition |
|---|---|---|
| Monthly starting rate | From $7/day or $199/month | Medicine assignment and included services |
| Monthly promotional block | $199 and $299/mo; $149 and $249; $50 off first month | Which price applies to which product |
| Three-month block | From $5.50/day or $166/month; $166 and $266/mo; $116 and $216; $50 off first month | Total collection, product assignment, and billing interval |
| Separate three-month promotion | $99 off total, described as $33/mo off | Whether this combines with another offer |
| Separate first-month statement | First month for as little as $169 | How this relates to the plan blocks |
Ongoing care is promised, but its schedule is not documented
The homepage advertises ongoing provider access and support for cravings, and says the provider monitors treatment and remains available for adjustments. Those are meaningful service claims, but the public documents do not establish a contact schedule, appointment length, response-time standard, or after-hours availability. They also do not describe whether cravings support means clinician messaging, structured counseling, another resource, or a combination. A prospective patient cannot determine the practical intensity of care from the promise of access alone.
The cancellation policy provides an additional operational clue: a clinician may discontinue treatment when it is no longer appropriate, safety concerns arise, or the patient does not respond to outreach for required follow-up. If discontinuation occurs before a scheduled shipment, that shipment will not be charged. This establishes that follow-up can be required and clinically consequential, even though its frequency and format are not published. It does not establish that a subscription automatically continues treatment regardless of response.
A useful consultation question is therefore not simply whether support exists, but what happens after a patient reports a problem or misses a check-in. Ask who receives messages, who decides whether another evaluation is needed, and how care is coordinated with existing therapy or recovery support. Our guide to clinical follow-up beyond renewal notices explains this distinction. For Livelyhood specifically, the documents support an ongoing-care promise, but not a measured level of responsiveness or a verified standard of monitoring.
Cancellation and refunds depend on what has already happened
Livelyhood allows cancellation through the account or by emailing support@findlivelyhood.com, with cancellation effective at the end of the current billing cycle. Its policy separately says cancellation before a scheduled shipment processes prevents that shipment and further charges. These provisions make shipment status important. The documentation does not give a specific advance-notice deadline or fully explain how renewal and processing interact, so “cancel anytime” should not be interpreted as an immediate refund of an already started cycle.
The initial consultation fee is fully refundable if the clinician determines the patient is not a candidate and no medication ships. Once the evaluation is completed and a prescription issued, that fee becomes nonrefundable. Medication cannot be returned or refunded after shipment, including compounded preparations and the unnamed FDA-approved oral medicines referenced in the policy. Partial cycles are not prorated or refunded once the cycle begins and its associated consultation or medication has been delivered.
For the wrong medication or quantity, the policy instructs patients to stop using it and contact Livelyhood, which says it will arrange a correction and, where appropriate, a refund. Approved refunds are typically issued to the original payment method within five to ten business days, depending on the bank; that is not a guaranteed bank-receipt date. Separately, the terms provide binding individual arbitration with an email opt-out within 30 days of first acceptance, using the subject line “Arbitration Opt-Out.”
Privacy promises have defined limits
Because Livelyhood addresses alcohol use, its intake can involve particularly sensitive disclosures. The privacy policy describes collecting medical and medication history, behavioral-health and substance-use history, previous treatment, height, weight, uploaded photographs, and information shared during consultations. This is more specific than a general wellness questionnaire. The policy also recognizes requests for a copy of the medical record and corrections to information considered inaccurate or incomplete, useful provisions for someone coordinating records across several care settings.
Livelyhood says it does not sell personal information or use protected health information for marketing to third parties without authorization. That does not amount to absolute secrecy. The policy allows disclosures required by law, valid legal process, protection of rights and safety, adverse-event reporting, and other circumstances permitted by HIPAA. Readers should interpret the company’s confidentiality messaging alongside these stated exceptions, rather than assuming that no information can ever leave the platform.
The company describes encryption in transit and at rest, access controls, audit logging, workforce training, and vendor-risk management. It also expressly says no system is perfectly secure and it cannot guarantee absolute security. These statements document the safeguards the company says it uses; they are not an independent security audit. The consulted pages likewise do not establish Spanish-language care, interpretation services, or support in other languages, so those access needs should be clarified directly rather than assumed.
Questions & answers
Is Livelyhood primarily a weight-loss provider?
Not according to the reviewed documents. Its privacy policy identifies alcohol use disorder as the platform’s treatment focus. The homepage differentiates semaglutide for drinking less without weight loss from tirzepatide for drinking less with some weight loss. Those descriptions are marketing claims, not verified outcomes or guarantees. A reader should evaluate this as an alcohol-focused telehealth offering rather than assume that the presence of GLP-1 medicines makes it a conventional obesity program.
Does paying Livelyhood guarantee a prescription?
No. The terms explicitly allow the clinician to decline prescribing, propose another treatment, request more information, or require in-person care. Evaluation may use secure messaging or video when clinically appropriate. The consultation fee is refundable under the stated policy when the clinician determines the person is not a candidate and no medication ships. The documents do not publish that fee’s amount or clearly explain whether it is separately collected or included in a plan.
Which Livelyhood price should I expect to pay?
The public pricing does not resolve one definitive charge. Monthly advertising starts at $199 per month, while three-month advertising starts at $166 per month; separate blocks show other amounts, first-month discounts, and a first month from $169. Ask for a written, product-specific checkout total and renewal amount. Also confirm whether the three-month option is collected upfront or in installments, what services are included, and whether the advertised promotions combine. The reviewed pages do not settle those questions.
Can I select my dispensing pharmacy?
The terms do not promise patient choice among the listed partners. They say assignment depends on the medicine, state of residence, and clinical considerations. The four named partners are RedRock Pharmacy, Health Warehouse, Precision Medicine, and Triad Rx. Before treatment, ask which pharmacy will fulfill the specific prescription and what exact product, route, and presentation it will dispense. The partner list alone does not answer those product-level questions or independently verify the pharmacies’ licensing claims.
Does canceling mean I receive my money back?
No. Cancellation takes effect at the current cycle’s end, and the policy limits refunds after evaluation, prescription issuance, shipment, or delivery of associated services. Medication is nonreturnable and nonrefundable once shipped. The policy says canceling before a scheduled shipment processes prevents that shipment and further charges. Use the account or support@findlivelyhood.com, and clarify shipment status when requesting cancellation. Any approved refund is typically issued within five to ten business days, not guaranteed to arrive in the bank within that window.
What should I clarify about follow-up before enrolling?
Ask how frequently reviews occur, whether they use messaging or video, who responds to concerns, expected response times, and what support is available outside normal hours. Livelyhood advertises ongoing provider access and monitoring but does not publish those operational details. Its policy permits treatment discontinuation for failure to respond to required follow-up. Also clarify whether the cravings support advertised on the homepage includes counseling or another structured service, rather than assuming that every form of recovery support is included.
Our assessment
Livelyhood documents a recognizable service structure: an alcohol-focused platform, independent OpenLoop-affiliated clinicians, named pharmacy partners, remote evaluation, ongoing-access promises, and policies addressing cancellation and fulfillment problems. Those details are useful and more informative than promotional claims alone. They do not, however, establish effectiveness for its advertised “microdose” programs. The most consequential gaps are the exact prescribed product, evidence applicable to that regimen and purpose, the practical intensity of follow-up, and an internally consistent explanation of price. Weight-management trials cannot fill those gaps for an alcohol-treatment service. Before making a financial commitment, a prospective patient would benefit from written answers identifying the proposed formulation and route, the clinician’s rationale, the assigned pharmacy, the complete first and subsequent charges, and the response process for clinical concerns. The balanced conclusion is neither an endorsement nor a finding of ineffectiveness: Livelyhood describes a concrete offering, but the reviewed documentation leaves its treatment-specific evidence and several purchase conditions unresolved.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.